A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer

Chiara Paglino, Giuseppe Procopio, Roberto Sabbatini, Joaquim Bellmunt, Manuela Schmidinger, Alessandra Bearz, Aristotelis Bamias, Bohuslav Melichar, Ilaria Imarisio, Carmine Tinelli, Camillo Porta

Research output: Contribution to journalArticlepeer-review


Background/Aim: the ideal sequence of targeted agents for advanced kidney cancer is still unknown. In the present study we assessed the clinical benefit of two different sequential approaches, namely sorafenib, an inhibitor of mammalian target of rapamycin (mTORi) and sunitinib, or sunitinib (an mTORi) and sorafenib. Patients and Methods: we retrospectively reviewed the outcome of 40 advanced kidney cancer patients treated with one of the two above sequences. Results: a total of 26 patients were treated with the sequence sorafenib-mTORi-sunitinib and 14 with the sequence sunitinib-mTORi-sorafenib. The actuarial overall median progression-free survival (PFS) in the sorafenib-mTORi-sunitinib group and in the sunitinib-mTORi-sorafenib group were 21.9 and 22.8 months, respectively (log-rank test: p=0.928). In the sorafenib-mTORi- sunitinib group, patients in first-, second- and third-line therapy experienced PFS of 11.7, 5.1 and 9.1 months, respectively, while in the sunitinib-mTORi-sorafenib group PFS was 14.4, 4.3, and 3.9 months, respectively. Conclusion: Our results suggest there is no significant difference between the two sequence modalities.

Original languageEnglish
Pages (from-to)4999-5004
Number of pages6
JournalAnticancer Research
Issue number11
Publication statusPublished - Nov 2013


  • Drug sequence
  • Everolimus
  • Kidney cancer
  • Sorafenib
  • Sunitinib
  • Temisrolimus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer'. Together they form a unique fingerprint.

Cite this